**Table 1** Demographics of patients on rivaroxaban and apixaban

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Rivaroxaban** | | **Apixaban** | | **Total** |
| Patients, *N* | 106 | | 40 | | 146 |
|  |  |  |  |  |  |
| Daily dose, n (%) | 15mg daily  20mg daily | 25 (23.6)  81 (76.4) | 2.5mg BD  5mg BD | 6 (15.0)  34 (85.0) |  |
|  |  | |  | |  |
| Gender, n (%)  Male  Female | 77 (72.6)  29 (27.4) | | 32 (80.0)  8 (20.0) | | 109 (74.7)  37 (25.3) |
| Age (years), mean ± SD | 64.1 ± 9.5 | | 66.4 ± 7.4 | | 64.7 ± 9.0 |
| BMI (kg/m2), median (IQR) | 26.0 (23.5 – 30.3) | | 26.2 (22.8 – 28.2) | | 26.0 (23.4 – 29.7) |
| CrCl (mL/min), median (IQR)a | 71.0 (55.2 – 85.2) | | 61.9 (46.0 – 77.1) | | 67.7 (54.1 – 85.0) |
| Previous major bleed, n (%) | 7 (6.6) | | 2 (5.0) | | 9 (6.2) |
| Previous SSE, n (%) | 17 (16.0) | | 9 (22.5) | | 26 (17.8) |
| CHA2DS2-VASc, median (IQR) | 2 (2 – 3) | | 3 (2 – 4) | | 2 (2 – 3) |
|  |  | |  | |  |
| SSE, n (%)b  Bleeds, n (%)b  ISTH major bleeds  ISTH minor bleeds | 2 (2.1)  29 (29.9)  2 (2.1)  27 (27.8) | | 1 (2.7)  4 (10.8)  0 (0.0)  4 (10.8) | | 3 (2.2)  33 (24.6)  2 (1.5)  31 (23.1) |
| Abbreviations: *BD* twice daily, *SD* standard deviation, *BMI* body mass index, *IQR* inter-quartile range, *CrCl* creatinine clearance, *SSE* stroke and systemic embolism, *ISTH* International Society on Thrombosis and Haemostasis.  a There were missing data for this variable in the dataset. Median (IQR) for this variable is presented based on available data (Rivaroxaban: *N* = 102; Apixaban: *N* = 34).  b There were patients excluded for this variable. n (%) for this variable is presented based on included patients (Rivaroxaban: *N* = 97; Apixaban: *N* = 37). | | | | | |